Lifeline Biotechnologies, Inc. Completes Exchange of Preferred Shares for Common Shares

RENO, Nev.--(BUSINESS WIRE)--Lifeline Biotechnologies, Inc. (Pink Sheets:LBTN) announced today that the exchange of Preferred Shares for Common Shares has been completed.

Jim Holmes, CEO of Lifeline Biotechnologies, stated, "The exchange of Preferred Shares for Common shares has been completed as a part of the capital restructuring of the Company. We anticipate that the exchange could provide the participating shareholders an opportunity to benefit from the impending reverse split of the remaining common shares, which is being considered by the Board of Directors."

About Lifeline Biotechnologies, Inc.

The Company will focus on completing the development of the First Warning System(TM), designed to assist in the early detection of breast cancer. The underlying technology, upon which the First Warning System(TM) is based, holds the possibility of eliminating over 90% of unnecessary breast biopsies performed each year providing a potential savings of up to $2.8 billion annually. Additionally, the First Warning System(TM) could conceivably eliminate the need for suggested MRIs, a savings of another $1.3 billion. Of the approximately $138 billion spent on cancer each year, Lifeline could potentially save the healthcare industry up to $4.1 billion annually. Upon successful completion of the development of the First Warning System(TM), conducting clinical trials and obtaining FDA pre-marketing clearance, Lifeline will commence marketing its breast cancer early detection system. More information is available at the Company's website: www.lbtn.com.

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

Contact:

for Lifeline Biotechnologies, Inc.
Rodney Marvel, Investor Relations
1-866-THE-APPL(E)
www.lbtn.com